Cancers gynécologiques

DS6000-109

A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.
  • Open at Saint-Cloud since : 11/10/2024
  • Target : Adult
  • Phase : Phase II/III

Trial description

To evaluatecBICR-assessed ORRcat each dose level of;R-DXd.;To evaluate investigator-assessed ORR at each dose;level of R-DXd.;To evaluate the DoR at each dose level of;R-DXd.
Url of the trial

Main investigator